West Bancorporation Inc. Acquires New Shares in Abbott Laboratories (NYSE:ABT)

West Bancorporation Inc. acquired a new stake in Abbott Laboratories (NYSE:ABTGet Rating) during the fourth quarter, Holdings Channel reports. The fund acquired 2,062 shares of the healthcare product maker’s stock, valued at approximately $290,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ABT. Jackson Wealth Management LLC lifted its holdings in Abbott Laboratories by 2.1% in the third quarter. Jackson Wealth Management LLC now owns 34,368 shares of the healthcare product maker’s stock valued at $25,000 after acquiring an additional 722 shares during the last quarter. Blue Bell Private Wealth Management LLC purchased a new stake in Abbott Laboratories in the fourth quarter valued at approximately $30,000. Consolidated Planning Corp purchased a new stake in Abbott Laboratories in the third quarter valued at approximately $36,000. Strategic Asset Management LLC purchased a new stake in Abbott Laboratories in the third quarter valued at approximately $41,000. Finally, Altshuler Shaham Ltd purchased a new stake in Abbott Laboratories in the third quarter valued at approximately $46,000. Hedge funds and other institutional investors own 73.01% of the company’s stock.

In related news, EVP Mary K. Moreland sold 400 shares of the firm’s stock in a transaction that occurred on Tuesday, February 22nd. The shares were sold at an average price of $119.31, for a total transaction of $47,724.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Julie L. Tyler sold 462 shares of Abbott Laboratories stock in a transaction on Tuesday, February 22nd. The shares were sold at an average price of $119.29, for a total transaction of $55,111.98. The disclosure for this sale can be found here. Insiders have sold 7,896 shares of company stock valued at $926,454 in the last quarter. Insiders own 0.52% of the company’s stock.

A number of brokerages have issued reports on ABT. Morgan Stanley cut their target price on Abbott Laboratories from $157.00 to $151.00 and set an “overweight” rating on the stock in a research report on Thursday, January 27th. Bank of America began coverage on Abbott Laboratories in a research report on Tuesday, March 1st. They issued a “buy” rating and a $140.00 target price on the stock. StockNews.com began coverage on Abbott Laboratories in a research report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Wells Fargo & Company cut their price objective on Abbott Laboratories from $155.00 to $150.00 and set an “overweight” rating on the stock in a research report on Friday, April 8th. Finally, Royal Bank of Canada cut their price objective on Abbott Laboratories from $146.00 to $143.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Buy” and a consensus target price of $138.83.

NYSE:ABT traded down $4.51 during trading hours on Friday, hitting $113.50. The company’s stock had a trading volume of 6,815,890 shares, compared to its average volume of 4,802,289. The company has a current ratio of 1.85, a quick ratio of 1.46 and a debt-to-equity ratio of 0.48. Abbott Laboratories has a 52-week low of $105.36 and a 52-week high of $142.60. The stock has a market capitalization of $200.15 billion, a P/E ratio of 26.33, a price-to-earnings-growth ratio of 3.09 and a beta of 0.74. The stock has a fifty day moving average of $119.21 and a 200-day moving average of $125.54.

Abbott Laboratories (NYSE:ABTGet Rating) last released its quarterly earnings data on Wednesday, April 20th. The healthcare product maker reported $1.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.26. Abbott Laboratories had a net margin of 17.35% and a return on equity of 28.87%. The company had revenue of $11.90 billion during the quarter, compared to the consensus estimate of $11 billion. During the same quarter in the prior year, the firm posted $1.32 earnings per share. Abbott Laboratories’s revenue for the quarter was up 13.8% on a year-over-year basis. On average, sell-side analysts forecast that Abbott Laboratories will post 4.82 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 16th. Shareholders of record on Friday, April 15th will be paid a $0.47 dividend. The ex-dividend date is Wednesday, April 13th. This represents a $1.88 annualized dividend and a yield of 1.66%. Abbott Laboratories’s dividend payout ratio is presently 43.62%.

About Abbott Laboratories (Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Featured Articles

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTGet Rating).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.